Equity Overview
Price & Market Data
Price: $8.01
Daily Change: -$0.22 / 2.75%
Daily Range: $7.63 - $8.30
Market Cap: $398,070,720
Daily Volume: 1,109,400
Performance Metrics
1 Week: -7.17%
1 Month: -13.85%
3 Months: 9.12%
6 Months: -6.29%
1 Year: -36.85%
YTD: 2.20%
Company Details
Employees: 353
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.